cardiovascular disease
- United States
HD Medical Announces Key Hires to Fuel Accelerated Growth
Santa Clara, Calif., United States: HD Medical Inc. today announces additions to its executive team and advisory board to support…
Read More » - India
Ministry of Health & Family Welfare 2020 ACHIEVEMENTS
Steps taken by the Government of India for COVID-19 containment and management The WHO declared COVID-19 a pandemic on 11th…
Read More » - United States
Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Ingelheim, Germany & Indianapolis, United States: – In new results published in The Lancet Diabetes & Endocrinology, empagliflozin reduced the risk of total…
Read More »